Introduction
The chemokine system is intimately involved in leukocyte homeostasis and directing immune cells to sites of infection or inflammation (Viola and Luster, 2008) . Inappropriate expression of chemokine ligands or their respective G-protein coupled receptors (GPCRs) can result in disproportionate infiltration of specific immune cells into (inflamed) tissues or confer chemokine sensitivity to cells, normally non-responsive to chemokines (O'Hayre et al., 2008) . Ultimately, this leads to development of autoimmune diseases, chronic inflammation, or tumor growth and metastasis (Koelink et al., 2012) .
Chemokines are the endogenous peptide ligands of chemokine receptors with molecular weights of approximately 10 kDa. Chemokines are 10-50 fold larger than the average small molecule that binds these receptors. Nonetheless, many of these small ligands are able to inhibit chemokine-induced responses and/or the binding of these chemokines with nanomolar potencies (Scholten et al., 2012a) .
Intuitively, such size differences would suggest allosteric non-competitive mechanisms of action for small-molecule antagonists acting via distinct binding sites. In general, the interaction of chemokines with their receptors can be described by a two-step model, in which a chemokine first binds to the Nterminus of its respective GPCR. Subsequently, the N-terminus of the chemokine is positioned such that it interacts with the extracellular loops (ELs) and transmembrane (TM) domains of the GPCR. The lack of structural data on chemokine-GPCR binding hinders molecular understanding on how small molecules act at this subclass of family A GPCRs. Fortunately, structural information on chemokine receptors has started to emerge with the recent publication of chemokine receptor CXCR4 and CCR5 crystal structures (Wu et al., 2010; Tan et al., 2013) , opening up new possibilities for structure-based drug design on the chemokine receptor family (Kooistra et al., 2013; Scholten et al., 2012a) . In general, three pockets are distinguished in GPCRs, two in the TM domains, including the minor pocket or TM site 1 (TMS1) lined by TM helices 1 and 2, and the major pocket (transmembrane site 2 or TMS2) delimited by helices 4, 5, and 6 (figure 1A). Residues in helices 3 and 7 constitute the interface between both pockets, pointing either to one or the other pocket. Furthermore, a third pocket, lining the intracellular surface of the GPCR, was recently suggested as binding site for certain CXCR2 ligands (Nicholls et al., 2008; Salchow et al., 2010) . In CXCR4, the small molecule IT1t binds in TMS1, whereas the CVX-15 peptide interacts only with residues in TMS2, showing that ligands for the same receptor can bind to different pockets in the TM domains of chemokine receptors (Wu et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. The CXC Chemokine receptor CXCR3 is a key regulator of T-cell responses and has been linked to several diseases. Overexpression of the CXCR3 receptor and/or its ligands (CXCL9, CXCL10, CXCL11) is often observed in e.g. rheumatoid arthritis and transplant rejection (Lacotte et al., 2009 ).
In the past decade, many efforts have focused on discovery of small molecule CXCR3 antagonists, leading to the disclosure of ligands with a multitude of different chemotypes (Wijtmans et al., 2010; Wijtmans et al., 2008) . Initially, 8-azaquinazolinone compounds from Amgen (AMG487) and Neurocrine Biosciences (NBI-74330) were shown to bind CXCR3 with nanomolar affinities (Heise et al., 2005; Johnson et al., 2007; Verzijl et al., 2008) , and are effective in animal models of disease (van Wanrooij et al., 2008; Walser et al., 2006) . AMG487 was even assessed in clinical trials for treatment of psoriasis, but was discontinued after a phase IIa trial ). Moreover, a piperazinylpiperidine compound class with high affinity CXCR3 ligands has been disclosed by Schering Plough (now Merck-Sharp & Dohme) (McGuinness et al., 2006; McGuinness et al., 2009; Shao et al., 2011) .
This compound series is effective in rodent models of CXCR3-associated disease, including transplant rejection and rheumatoid arthritis (Jenh et al., 2012) .
Despite the interest in small-molecule antagonists for CXCR3, little information is available about their interaction with CXCR3 at the molecular level; as whether they bind to TMS1, TMS2, or both. In this study, we aimed to elucidate the binding mode of two high-affinity CXCR3 ligands from the 8-azaquinazolinone and the piperazinyl-piperidine class using site-directed mutagenesis complemented with in silico modeling of CXCR3. We show that NBI-74330, from the azaquinazolinone class from Amgen (figure 1) (Heise et al., 2005; Johnson et al., 2007) mainly binds to TMS1 whereas a chlorobenzyl derivative of the piperazinyl-piperidine class disclosed by Merck (McGuinness et al., 2006) with one of the highest CXCR3 affinities reported to that date (named VUF11211, figure 1) , binds to both TMS1 and TMS2.
This article has not been copyedited and formatted. The final version may differ from this version. CXCR3 ligands. VUF11211 (compound 18i in ) was synthesized in enantiopure form in our group according to the general synthetic procedures patented by Merck (McGuinness et al., 2006) . Details of the synthetic procedures are provided in the Supplemental Information (Supplemental Methods). The synthesis of NBI-74330 has been described before (Storelli et al., 2007) .
DNA Constructs and Site-Directed Mutagenesis. The DNA coding for human CXCR3 was a gift from Prof Dr. B. Moser (Cardiff University School of Medicine, Cardiff, UK) and was inserted in the expression vector pcDEF 3 . Mutants were generated by using PCR primers containing one or more mismatches in the center of the primer, flanked by 15-20 base pairs. At first, two individual polymerase chain reactions (PCRs) were performed simultaneously to amplify the first part of the receptor until the desired mutation, and the second part of the receptor from the mutation until the BGH polyA sequence. The forward primer used to generate the first part (pcDEF 3 -FW; 5'-gggtggagactgaagttaggcc-3') recognizes part of the EF1α promoter, whereas the reverse primer for the second part (pcDEF 3 -RV; 5'ggaaggcacgggggaggggc-3') targets part of the BGH polyA sequence of the vector. The reverse primer for the first part and forward primer for the second, are reverse complementary and recognize CXCR3 around the desired mutation as mentioned above. See the Supplemental Information for the sequences of these mutation-specific primers (Supplemental Table   1 ). Subsequently, a second PCR with primers pcDEF 3 -FW and pcDEF 3 -RV was performed to fuse both receptor DNA fragments, making use of the overlapping sequence in both individual parts as internal primer. Finally, the resulting products were digested using BamHI and XbaI restriction enzymes and ligated into pcDEF 3 . Sequences were confirmed using Sequencing (Macrogen,
Amsterdam, The Netherlands).
This article has not been copyedited and formatted. The final version may differ from this version. (Wu et al., 2010) ). The primary sequence of CXCR3 (Genbank accession no. P49682) was aligned to that of the CXCR4 crystal structure. The N-terminal residues 1 to 41 were omitted from the model due to a lack of crystallographic data. An initial model was constructed for the CXCR3−VUF11211 complex as a basis for the binding model for NBI-74330. VUF11211 was docked into the model using GOLD v4 (Verdonk et al., 2003) . Subsequently, protein-ligand interactions were optimized in MOE by energy minimization during which all heavy atoms were tethered with a 10.0 kcal/mol restraint, similar to the protocol our group recently described (de Kruijf et al., 2011) . However, since the CXCR4−IT1t template contains lipids protruding into protein between TM5 and TM6 and the C-terminus blocking the extracellular opening (Roumen et al., 2012) , the binding pocket of a CXCR3 model is spacious and VUF11211 cannot form an interaction with W268 6.48 . To explain all site-directed mutagenesis data, the CXCR3 model was optimized within this region by moving TM6 by 2Å closer to TM3 and TM5, followed by the same energy minimization protocol (de Kruijf et al., 2011) . This resulted in a TM arrangement comparable to that of the aminergic receptors (Shimamura et al., 2011) . Using the finalized CXCR3 model, NBI-74330 was docked into the protein pocket with GOLD resulting in a pose that is in accordance with the site-directed mutagenesis data from this study, and optimized by energy minimization.
Residue numbering throughout the manuscript is displayed as absolute sequence numbers with the Ballesteros-Weinstein notation in superscript (e.g. W109 2.60 ). If residues are compared between MOL #88633 performed as reported earlier (Scholten et al., 2012b Friedrichshall, Germany).
Membrane Preparation. Membrane preparation was performed as described previously . In brief, cell membrane fractions from HEK293T cells, transiently transfected with WT or mutant CXCR3, were prepared by washing with ice-cold PBS. Subsequently, the cells were collected in tubes and centrifuged at 1500g for 10 min. The pellet was resuspended in ice-cold membrane buffer (15 mM Tris, pH 7.5, 1 mM EGTA, 0.3 mM EDTA, and 2 mM MgCl 2 ), and homogenized using a Teflon-glass homogenizer and rotor. The membranes were subjected to two freeze-thaw cycles using liquid nitrogen, and centrifuged at 40,000 g for 25 min. The pellet was resuspended in Tris-sucrose buffer (20 mM Tris, 250 mM sucrose, pH 7.4) and aliquots were stored at -80°C. This article has not been copyedited and formatted. The final version may differ from this version. 
Radioligand Binding

Results
To dissect the binding modes of the two selected CXCR3 antagonists, we considered the homology between different chemokine receptors, focusing on residues that had previously been shown to be involved in the binding of small molecule antagonists to a variety of CC and CXC chemokine receptors. In figure 2 an alignment of transmembrane binding pocket residues from CC and CXC chemokine receptors is shown, with amino acid residues highlighted which affect ligand binding when mutated (de Mendonça et al., 2005; Jensen et al., 2007; Kondru et al., 2008; Vaidehi et al., 2006; Watson et al., 2005; Wong et al., 2008; Wu et al., 2010) . In the next sections we will focus on specific features of the different binding pockets.
Negatively charged ligand anchors
In general, small-molecule ligands for chemokine receptors are characterized by a positively charged quaternary ammonium and aromatic groups around it (Wijtmans et al., 2008) . This positive charge often contributes significantly to the affinity of the ligand, as observed for e.g. the bisaryl-and piperazinyl-piperidine class of CXCR3 ligands Wijtmans et al., 2011) . Calculations with Marvin tools (version 5.2.0, ChemAxon Kft, Budapest, Hungary) suggest that protonation of VUF11211 at pH 7.4 occurs at either the piperidine nitrogen (45%) or the trialkyl-nitrogen of the piperazine (43%), leaving 13% of the compound non-protonated.
As can be deduced from figure 2 a negatively charged glutamic acid at position 7.39 is highly conserved in the chemokine receptor family. This residue is often found to be the ionic anchor for a positive charge in chemokine receptor ligands, as for example for CCR1, CCR5, CXCR4, and viral chemokine receptor US28 (Casarosa et al., 2003; Kondru et al., 2008; Vaidehi et al., 2006; Wong et al., 2008 ). Yet, CXCR3 does not possess a negatively charged residue at this position and we therefore considered other potential anchors that could accommodate the positive charge in VUF11211. The chemokine receptor alignment in Figure 2 and the detailed information from the recently solved CXCR4 co-crystal structures, indicate that other negatively charged residues can also be involved in anchoring chemokine receptor ligands. Aspartates D2.63, D4.60 and D6.58 are e.g.
involved in binding of small ligands to CXCR4 (Wong et al., 2008; Wu et al., 2010) , whereas D2.63
has been shown to be involved in the binding of small molecule CXCR3 agonists (Nedjai et al., 2012) .
To identify the negatively charged residues in CXCR3 that act as partners for ionic interaction with the This article has not been copyedited and formatted. The final version may differ from this version. positively charged VUF11211 we started therefore this study by mutating 10 negatively charged aspartate or glutamate residues (see Table 1 ); seven residing in the TM domains, one in the Nterminus close to TM1, and two in extracellular loop (EL) 2. All these residues were mutated to asparagine, thereby preventing any ionic interaction.
Human embryonic kidney (HEK293T) cells were transiently transfected with cDNA coding for the CXCR3 wild type (WT) or mutant receptors. Next, protein expression levels were determined for each mutant using a whole-cell based ELISA ( figure   3C ) despite the absence of a positive charge in the compound.
Aromatic cages in CXCR3
Next to ionic interactions, many chemokine receptor ligands engage in interactions with hydrophobic aromatic amino acids present in the TM binding cavities of this receptor class. Figure 2 shows that many ligands appear to interact with such residues, including the conserved Y1.39 and W2.60 residues in TMS1, Y/F3.32 and F3.36 in the interface, and W6.48 and Y/F6.51 in TMS2 (Roumen et al., 2012; Scholten et al., 2012a) . These conserved residues form the so-called 'aromatic cages' within the transmembrane region in which hydrophobic and aromatic moieties of chemokine receptor antagonist can be are positioned (Surgand et al., 2006 (Kondru et al., 2008; Watson et al., 2005) , LMD-009 to CCR8 (Jensen et al., 2007) and AMD3100 (plerixafor) to CXCR4 (Wong et al., 2008 In chemokine receptors, W109 2.60 is a highly conserved tryptophan residue (figure 2) close to the TxP motif (Govaerts et al., 2001) , indicating that it is important for chemokine receptor stability and function, and W268 6.48 has been hypothesized as important for receptor function for numerous GPCRs Schwartz et al., 2006) . Several chemokine receptors feature a glutamine residue at these positions which is similar in size to a tryptophan, yet lacks aromaticity (figure 2). Therefore, W109 2.60 and W268 6.48 were selected for mutation to a glutamine. These mutant proteins were expressed at 81% and 60% compared to WT levels, respectively. Moreover, affinity of [
was unaltered at these mutants. The W268 6.48 Q mutation lowered the binding affinity of only VUF11211 (6-fold; pIC 50 from 7.8 to 7.0; table 2). Yet, the W109 2.60 residue appears to be very important for the binding of both NBI-74330 as well as VUF11211, as its mutation to glutamine led to a 500-and 630-fold decrease in affinity for NBI-74330 and VUF11211, respectively. (table 2; figure 3).
Hydrogen bonding
Next to aromatic stacking, also opportunities exist for the ligands to engage in hydrogen bonding with residues in the TM domains. As such, the serine (S301 7.36 and S304 7.39 ) and tyrosine residues (Y60 
Additional CXCR3 mutations
For several residues, additional mutants were constructed to investigate specific interactions. G128
3.29 is a variable residue among chemokine receptors indicating a location potentially important for selectivity between chemokine receptors. In addition, CXCR4 contains a histidine residue at this position, important for interaction with both IT1t and CVX-15 ligands (Wu et al., 2010) . Moreover, introduction of a histidine at this position (G128 3.29 H) in CXCR3 anchored small metal chelators to the receptor . As histidine is greater in size than glycine, the residue at this position was mutated to a histidine (G128 3.29 H) in analogy with CXCR4, to investigate the allowed space around this residue. This mutant was well expressed in HEK293T cells (80% of WT).
Interestingly, radioligand displacement potencies of CXCL11, NBI74330, and VUF11211 were all affected by this mutation, by 5, 100, or 800 fold, respectively (table 2), indicating that the larger histidine likely introduces a steric clash within the binding pocket of CXCR3 affecting the binding of all the ligands under investigation.
Finally, residue S304 7.39 was given special attention due to its analogous residue E7.39 which is relatively conserved in the chemokine receptor family and often involved in binding of small molecules (figure 2). Moreover, in CXCR4 the E7.39 interacts with the small-molecule antagonist IT1t compound in CXCR4 co-crystallized with this compound. In CXCR3, the S304 7.39 was mutated to a glutamic acid This article has not been copyedited and formatted. The final version may differ from this version. for which a loss in affinity of 80-fold was observed.
This article has not been copyedited and formatted. The final version may differ from this version. 
Proposed binding mode of VUF11211
Binding of VUF11211 to CXCR3 is affected by several mutations introduced in the TM domains, while binding of the endogenous agonist CXCL11 is largely unchanged. In addition, displacement of a radiolabeled variant of VUF11211 by CXCL11 was incomplete (Scholten et al., unpublished observations). Moreover, a closely-related compound (SCH-546738) exhibited non-competitive antagonistic behavior on CXCL11-mediated receptor activity (Jenh et al., 2012) . Overall, these findings indicate that VUF11211 affects the binding of CXCL11 to CXCR3 in an allosteric fashion.
Our CXCR3 mutation data and homology modeling studies indicate that VUF11211 interacts with residues in both TMS1 and TMS2 pockets ( Figure 4A ,C,E). We hypothesize that D186 4.60 serves as the anchor for the positive charge at the piperidine nitrogen of VUF11211, since a 10-fold drop in affinity was observed at the D186 4.60 N mutant (table 1; figure 4A ). This hypothesis is supported by SAR studies that highlight the importance of the basicity of the piperidine ring ( figure 4A ) . Rigidification of the benzyl moiety either by ring closure or intramolecular hydrogen bonding, at the cost of basicity, could maintain ligand affinity, indicating the importance of directionality for the chlorobenzyl moiety Shao et al., 2011) . In the proposed binding mode, the chlorobenzyl moiety resides in a small space between TM4 and TM5 (figure 4A,C,E). The importance of the S-ethyl moiety on the piperazine core was proven by various substitutions that showed a preference for a small apolar group over larger or polar moieties (McGuinness et al., 2009; Shao et al., 2011) . This implies that rotation of the pyridine and the piperidine rings with respect to the piperazine ring are restricted, and in addition, that there is limited space around the ethyl moiety. In our model the piperazine moiety is close to TM6 and the finding that W268 F) showed a 10-fold reduction in affinity, we suggest that at least these three residues that are in close proximity to VUF11211 and might form a hydrogen-bonding network within the CXCR3 binding pocket ( figure 4A,C) . Apparently, these amino acid residues are able to compensate for the removal of the hydrogen-bonding capabilities of a nearby residue. The involvement of hydrogen bonding is also indicated by mutation of S304 7.39 to glutamic acid or leucine.
The results obtained with the S304 ) is required, which is proposed to interact with the amide moiety. However, the introduction of a large hydrophobic group with S304 7.39 L reduces the affinity of VUF11211 by 20-fold.
Binding hypothesis of NBI-74330
Multiple mutations affected the binding of NBI-74330, whereas CXCL11 affinity remained unchanged.
Furthermore, NBI-74330 exhibited non-competitive insurmountable antagonism in various functional assays, including phospholipase C activation (Heise et al., 2005; Verzijl et al., 2008) . In addition, CXCL11 could not completely displace the radiolabeled closely-related NBI-74330 analogue RAMX3 (Bernat et al., 2012) . Altogether, these pharmacological data combined with our in-silico guided mutagenesis studies suggest an allosteric mode of action for NBI-74330.
Since NBI-74330 does not possess highly basic moieties and hence lacks H-bond donor atoms, the reduction of affinity observed at the D112 2.63 N mutant is remarkable (table 1; figure 3C ). The quinazolinone nitrogen atoms and associated positive partial charge on the 7-position of the ring is important for CXCR3 antagonism (Johnson et al., 2007; Liu et al., 2009; Storelli et al., 2007) . As such,
we propose that an aromatic -CH group of the 8-azaquinazolinone moiety of NBI-74330 forms a weak hydrogen bond to D112 2.63 , like N-heteroaromatic -CH groups in pyridine (Balevicius et al., 2007) and This article has not been copyedited and formatted. The final version may differ from this version. quinolin-8-ol rings ( figure 4D,F) . The ligand SAR and CXCR3 mutagenesis data however do not exclude indirect water-mediated H-bond interactions between the pyridine nitrogen and the carboxylate group of D112 2.63 , like the water-mediated H-bond network between the tetrazole moiety of maraviroc and the hydroxyl group of Y1.39 in the CCR5 crystal structure ( figure 5C ) (Tan et al., 2013) . In the proposed binding mode the quinazolinone ring stacks with W109 2.60 , which is corroborated by the site-directed mutagenesis data (500-fold reduction in NBI-74330 affinity at the W109 2.60 Q mutant). The ethoxy-phenyl moiety is located close to TM3, in line with the 100-fold reduction of NBI-74330 affinity at G128 3.29 H mutant, likely due to a steric clash in the mutant receptor ( figure 4D,F) .
The electron-withdrawing character of the trifluoromethyl moiety is also an important determinant for ligand affinity (>100-fold better over unsubstituted benzyl) (Storelli et al., 2005; Storelli et al., 2007) .
Polar aromatic interactions between CXCR3 and NBI-74330 are identified by F131 3.32 A, Y271 6.51 A and 
CXCR3 antagonist binding pockets
Different mutations in the TM region impacted NBI-74330 or VUF11211 binding, yet did not significantly affect CXCL11 affinity (figure 3), suggesting that CXCL11 does not bind to the TM domains (Xanthou et al., 2003; Trotta et al., 2009 ) and that these small molecules are allosteric CXCR3 ligands. However, chemokines are considerably larger, and most of their interaction energy comes from binding to the N-terminus and ELs of the receptor. A small part of the chemokine (Nterminus) is thought to interact with the receptor TM bundle for receptor activation. As such, potential overlap in interacting residues of the CXCR3 N-terminus and small molecules in TMS1/2 cannot be ruled out at this point.
Interestingly, and similar to CXCR2 and CXCR4, these ligands bind differentially in the TM pockets within CXCR3. In our homology model of CXCR3, NBI-74330 binds mainly to TMS1 residues ( figure   5A ), as also observed for the antagonist IT1t co-crystallized with the CXCR4 receptor (Wu et al., 2010) (figure 5B: cyan, versus figure 5A: magenta). NBI-74330 seems to span TMS2 to a small extent, This article has not been copyedited and formatted. The final version may differ from this version. (Jensen et al., 2007) , and IT1t in CXCR4 (D2.63 and E7.39) (Wu et al., 2010 ( figure 5A ). Interestingly, in a recent CCR5 crystal structure maraviroc also binds in both pockets (e.g. Y1.39, W2.60, Y3.32, W6.48, Y6.51, I5.42, E7.39 ) (Tan et al., 2013 ) ( figure 5C ), whereas in a CXCR4
crystal structure, the CVX-15 peptide exclusively binds to TMS2 (figure 5B) (Wu et al., 2010) . The relatively large CVX-15 peptide stretches out to the extracellular loops (figure 5B), while VUF11211
seems to bind in a more horizontal fashion ( figure 5A ). Ligands for other chemokine receptors also stretch both binding pockets, e.g. Y3.33, I6.55, Y7.43 ) (Vaidehi et al., 2006) , and AMD3100 in CXCR4 (Y1.39, W2.60, Y3.32, D4.60, D6.58, E7.39) (Wong et al., 2008; Wu et al., 2010 ). In conclusion, in this study we report for the first time the molecular details of the binding of two bold black text. Data is obtained from primary literature, reviewed in two recent reviews (Roumen et al., 2012; Scholten et al., 2012a) . Note that no data is included on ligands like metal chelators requiring modification of receptors to bind at all. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. N 110 ± 8 9.6 ± 0.2 8.1 ± 0.0 7.6 ± 0.1
Overview of both total receptor expression levels determined using whole cell-based ELISA, and affinity data for the three compounds. The latter was generated by performing [ 125 I]-CXCL11 radioligand displacement binding studies on membranes prepared from HEK293T cells transiently expressing CXCR3 WT or mutants. Shown values are averages ± SEM from at least three individual experiments. The Ballesteros-Weinstein residue numbers are indicated as superscript for residues in transmembrane (TM) helices, whereas the numbering scheme proposed by de Graaf and colleagues is used to enumerate residues in the second extracellular loop two (EL2) (Ballesteros and Weinstein, 1995; de Graaf et al., 2008) .
N.D. the affinity could not be determined due to lack of specific [ 125 I]-CXCL11 binding.
* pIC 50 value decreases with 10 fold or more.
# pIC50 value decreases between 5 to 10 fold.
